Mallinckrodt (NYSE: MNK) has received subpoenas from both the Securities and Exchange Commission and the U.S. Attorney’s office in Massachusetts in recent months, according to a federal filings.
In January, the company received a subpoena from the SEC for documents related to the sales, profits, promotion and pricing of Acthar, the company’s top-selling drug.
In December, Mallinckrodt received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts for documents related…
Mallinckrodt (NYSE: MNK) has received subpoenas from both the Securities and Exchange Commission and the U.S. Attorney’s office in Massachusetts in recent months, according to a federal filings.
In January, the company received a subpoena from the SEC for documents related to the sales, profits, promotion and pricing of Acthar, the company’s top-selling drug.
In December, Mallinckrodt received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts for documents related…